Evidence map›Paper›PMID 26510455›Full record

ArticleGastroenterology report2015

Immune checkpoints and immunotherapy for colorectal cancer.

Preet Paul Singh, Piyush K Sharma, Gayathri Krishnan, A Craig Lockhart

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology report, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Implication of gut microbes and its metabolites in colorectal cancer.Journal of cancer research and clinical oncology · 2023
    Review
  8. Review
  9. Article
  10. Efficacy of bivalentHeliyon · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Preet Paul SinghDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA and psingh@dom.wustl.edu.
Piyush K SharmaDepartment of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Gayathri KrishnanDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA and.
A Craig LockhartDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA and.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy-in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

Indexed as

checkpoint inhibition/blockadecolorectal cancercytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)immunotherapypembrolizumabprogrammed death 1 (PD-1)vaccine

Identifiers

PMID26510455
PMCPMC4650981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.